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Summary Objectives: A single centre pilot study to investigate the role of the plasma
N-terminal pro-brain natriuretic peptide (N-T proBNP) assay to risk stratify patients
with suspected pulmonary arterial hypertension (PAH) from a background SSc
population.
Methods: Out of 49 SSc patients, 23 had and 26 did not have PAH. Right ventricular
haemodynamic variables, six-minute walk test and plasma N-T proBNP levels were
recorded from patients catheterised for suspected PAH (23 with PAH and 11/26
without PAH).
Results: Mean value of N-T proBNP for SSc patients with PAH was 3365 (standard
error 1095) pg/ml compared to 347 (174) pg/ml for patients without PAH. There was a
statistically significant correlation (Po0:05) between N-T proBNP values and (i) mean
pulmonary artery pressure (r ¼ 0:53), (ii) right ventricular end diastolic pressure
(r ¼ 0:59) and (iii) pulmonary vascular resistance (r ¼ 0:49). Receiver operator
characteristic curve analysis showed that a cut-off value of 395.34 pg/ml had a
sensitivity of 0.69 and specificity of 1.0.
Conclusions: N-T proBNP estimation in systemic sclerosis-related pulmonary
hypertension is a potentially useful diagnostic tool with a high specificity and
negative predictive value. This test has the potential to have an important role in risk
stratification and monitoring of therapy in the future.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Brain natriuretic peptide (BNP) is a member of the
natriuretic peptide family, which consists of three
molecules that share significant amino acid se-
quence homologies and a looped motif. BNP was
first isolated from porcine brain but is produced
mostly from the ventricular myocardium.1 Secre-
tion is triggered from the cardiomyocyte, where
the BNP is initially synthesised in the pre–pro-form.
After cleavage of a signal sequence, the pro-form is
synthesised as a 108 amino acid precursor and
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appears in the circulation in two formsFa 76
amino acid peptide N-terminal pro-brain natriure-
tic peptide (N-T proBNP) molecule and the 32
amino acid physiologically active BNP peptide.
Elevated plasma levels are found in patients with
hypertensive left ventricular dysfunction, acute
myocardial infarction and unstable angina.2,3 Based
on these findings, the Breathing Not Properly
Multinational Study Investigators4 performed a
large prospective multicentre study and showed
BNP to be a useful screening test for congestive
cardiac failure. As with ANP, raised plasma BNP
levels promote both natriuresis and diuresis. They
also inhibit the renin–angiotensin–aldosterone sys-
tem and facilitate pulmonary vasodilatation.5 In
contrast to studies in left ventricular dysfunction,
there have been few studies on BNP levels in
patients with right ventricular dysfunction in the
background of pulmonary vascular disease.
Amongst patients with primary pulmonary hyper-
tension (PPH), Nagaya et al.6,7 have shown that
plasma BNP levels increase in proportion to the
degree of right ventricular dysfunction. These
authors measured plasma BNP levels using a BNP
ELISA assay in 53 patients with PPH at diagnostic
catheterisation, with a follow-up period of 18
months. Kaplan–Meyer analysis showed a wide
variation in survival, with patients with higher
plasma N-T proBNP levels having a worse survival.
Multivariate analysis confirmed BNP to be an
independent predictor of mortality in this condi-
tion.
Although right-heart catheterisation is the gold
standard for quantifying right ventricular dysfunc-
tion, the expertise required to accurately perform
this investigation is not readily available in many
units. In addition, right-heart cardiac catheterisa-
tion carries a serious complication rate of approxi-
mately one in 2000. Hence, it would be useful if a
non-invasive blood test could identify patients at
an increased risk of developing pulmonary arterial
hypertension (PAH) related to SSc, so that they
could be selected for invasive investigation and
managed as outlined in the recently published
guidelines by Gibbs.8
The role of BNP in SSc patients has never been
previously investigated. The majority of SSc pa-
tients are believed to suffer from subclinical
cardiac fibrosis,9 which is difficult to identify at
its prefibrotic ‘‘inflammatory’’ stage. Hence, the
existence of this presumed low-level inflammatory
activity predisposing to fibrosis has been difficult to
demonstrate. Thus, BNP levels could be elevated in
the SSc population at large, diminishing its value as
a discriminative test in the setting of sclerosis-
related pulmonary arterial hypertension (SScPAH).
Yet, this is also the population with the highest
incidence of PAH, and the only population in which
annual screening is considered essential.10 Current
non-invasive screening techniques (echocardiogra-
phy and pulmonary function tests) lack sensitivity
and specificity11 and are not readily accessible in
all centres. The availability of a reliable blood test
to screen for PAH in the SSc population would
significantly improve patient care.
Newer assays have been recently developed that
accurately measure N-T proBNP.12 The clinical
suitability of this assay is superior to those that
have previously measured the active plasma BNP. In
contrast to the 32 amino acid-active BNP, this form
of the secreted peptide is highly stable in plasma at
room temperature for up to 72 h and can be stored
for45 days at a refrigerator temperature of 4–81C.
Additionally, there is no variation of levels detected
by this assay which is dependent on either circadian
rhythm or the position of the test person (lying/
sitting position or after stress exposure). This
makes the N-T proBNP an ideal assay in the clinical
setting with a high internal accuracy.13 Hence,
given that the test can be performed under routine
laboratory conditions, it would be important to
evaluate its usefulness in patients with SSc in
general and PAH in particular.
Aims
The aim of our pilot study were first to determine
whether circulating plasma N-T proBNP levels
would discriminate between patients with and
without PAH in the setting of SSc. Second, to
determine whether absolute N-T proBNP levels in
SSc patients with PAH correlated with haemody-
namic and functional (the six-minute walk test
(SMWT))14 indices of disease severity.
Method
Population
Forty-nine patients with SSc as defined by the
revised ACR criteria15 were enrolled in the pilot
study. Out of 49 patients, 23 had SScPAH confirmed
on cardiac catheter as defined by the modified NIH
criteria.16 Twenty-six patients had SSc but no
evidence of PAH on lung function tests and
echocardiography. Of these 26 SSc patients, 11
underwent cardiac catheterisation for investigation
of breathlessnessFPAH was excluded in all.
Patients with PAH had a mean age of 57 years
(range 34–80 years). The control subjects had a
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mean age of 56 years (range 27–78 years). The
haemodynamic and lung function characteristics of
the 23 patients with PAH and 26 controls is shown in
Table 1. Patients with significant renal disease were
excluded from the study (creatinine 41.5mg/dl)
as plasma BNP levels have previously been reported
to be elevated in chronic renal failure.17 SMWTs
were performed on all patients found to have PAH
within 1 month of the N-T proBNP estimation. We
compared N-T proBNP values with the patient’s
functional state as measured by the SMWT.
Screening and diagnostic programme for PAH
The Royal Free Hospital, London is a national
referral centre for patients with SSc. Seven
hundred and ninety four patients are under active
follow-up. All patients are screened on an annual
basis for evidence of PAH. Patients with an increase
in breathlessness are evaluated invasively unless
there has been clear progression in lung fibrosis
both radiologically and on lung function testing. All
are screened by standardised echocardiographic
evaluation of the right ventricle and tricuspid
gradient (using the Sonitron CFM 800 machine,
Oslo, Norway), and by lung function assessment.
Patients with tricuspid gradient 435mmHg, or
evidence of right ventricular strain, and those with
a 20% reduction in DLCO compared to the previous
value, or a DLCO o40% with no lung fibrosis on
HRCT are evaluated by right-heart catheterisation
irrespective of the presence of symptoms. Breath-
less patients not found to have PAH on right-heart
catheter underwent left-heart catheterisation to
investigate for a cause of their symptoms. Hence,
11 out of 26 SSc patients who were chosen as
control subjects underwent left- and right-heart
cardiac catheterisation as they were clinically
found to have an increase in their level of breath-
lessness.
N-T proBNP measurement
Approval was obtained from the hospital ethics
committee. Each patient gave signed informed
consent allowing measurement of plasma N-T
proBNP levels. A 10ml whole blood sample was
drawn from each patient into a heparinised (EDTA)
plastic tube. This was transported at room tem-
perature to the chemical pathology department
and the assay was performed within 4 h of blood
sampling. The plasma N-T proBNP level was
measured with the Elecsys Systems E170 proBNP
assay kit by two of the above authors (P.A. and
D.N.). The assay calculated the N-T proBNP
concentration of each sample in values of pg/ml.
Expected value for women at age o50 years
was 153 pg/ml, 50–65 years were 334 pg/ml, for
men at age o50 was 88 pg/ml and 50–65 years was
227 pg/ml.
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Table 1 Characteristics of 49 SSc patients undergoing N-T proBNP estimation, cardiac catheterisation and functional
(SMWT) evaluation.
Category (N ¼ 49) Patients with SScPAH (N ¼ 23) SSc patients without PAH (N ¼ 26)
Age with range 57 (34–80) years 56 (27–78) years
M:F 2:21 7:19
Autoantibody profile ACAþ 18, ANAþ 4, Scl 70þ 1 ACAþ 19, ANAþ 5, Scl 70þ 2
LcSSc:DcSSc 21:2 23:3
Patients with pulmonary fibrosis (on HRCT) 0 1
% predicted DLCO (mean72 SD) 56.773.2 7274.7
MPAP (mmHg) 44.5713.5 19.874.1a
MRAP (mmHg) 7.774.8 2.171.2
MAP (mmHg) 93.9715.6 98711.2
PVR 6877564 102714
SVR 17137606 18427532
CI 2.671.4 4.171.2
SVO2 63.9710.7 85.2711.0
% predicted DLCO in mmol/min/kPa, calculated assuming Hb¼ 13.5mg/ml. MRAP¼mean right atrial pressure in mmHg;
MPAP¼mean pulmonary artery pressure in mmHg; MAP¼mean arterial pressure in mmHg; PVR¼pulmonary vascular resistance
in dyne s/cm5; SVR¼ systemic vascular resistance in dyne s/cm5; CI¼ cardiac index in l/min/m2; SVO2¼mixed venous oxygen
content in ml/dl.
aNote: Haemodynamic data available from 11/26 SSc patients undergoing cardiac catheterisation.
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Haemodynamic studies
Diagnostic right-heart catheterisation was per-
formed on 34 SSc patients (23 patients with SSc
PAH and 11 controls with SSc but no PAH) within 3
months of N-T proBNP estimation. Baseline haemo-
dynamic variables were measured, including mean
pulmonary arterial pressure (mean PAP), pulmonary
capillary wedge pressure (PCWP), right ventricular
end diastolic pressure (RVEDP) and cardiac output
by the thermodilution method. Pulmonary vascular
resistance (PVR) was calculated by the formula
(mean PAPPCWP) 80/cardiac output. All pa-
tients with pulmonary hypertension underwent
vasodilator testing.
Statistics
The Stat Direct18 statistics package and Microsoft
Excel was used for statistical calculations. Mean
values of BNP were expressed along with standard
error (SE) of the mean and compared between
patients with PAH and controls. Linear regression
analysis was used to determine correlation be-
tween plasma BNP levels and mean PAP, RVEDP as
well as PVR.
The receiver operating characteristic (ROC)
curve method of analysis was used to assess the
diagnostic value of BNP in patients with PAH
compared to controls.
Results
Correlation of plasma N-T proBNP levels with
haemodynamic indices
Mean value of N-T proBNP (SE) for patients with PAH
was 3365 (1095) pg/ml compared to 347 (1 7 4) pg/
ml for those without PAH (Fig. 1). This indicates
that plasma N-T proBNP levels are slightly elevated
in SSc patients (controls) but they are elevated to a
significantly higher magnitude in patients with PAH.
Amongst the latter, there was a significant positive
correlation between plasma N-T proBNP levels and
mPAPs (Fig. 2) (r2 ¼ 0:28; Po0:05). It was notable
that the four patients with significant PAH with
mPAP of 60mmHg on cardiac catheter had a wide
variation in their N-T proBNP values between
1500–13,000 pg/ml. A similar correlation was found
between RVEDP (Fig. 3) and plasma N-T proBNP
levels. Similarly, there was a significant correlation
between PVR and N-T proBNP levels (PVR in dynes/
s5, normal range up to 140. Correlation coefficient
r ¼ 0:49 (r2 ¼ 0:24; Po0:05), SE¼ 0.87). All correla-
tions were statistically significant with Po0:05:
Correlation of plasma N-T proBNP levels with
functional state
The comparison between the patient’s functional
state as measured by the SMWT showed that
patients with increased severity of disease as
reflected by decreased exercise capacity had high-
er plasma N-T proBNP levels (Fig. 4).
ARTICLE IN PRESS
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
PHT       Control
B
N
P
Figure 1 Mean N-T proBNP values (pg/ml) with SE (bars)
comparing PAH and control SSc patients.
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Figure 2 Correlation between N-T proBNP values (pg/
ml) and mean PAP (mmHg) on cardiac catheter. Correla-
tion coefficient r ¼ 0:53 (r2 ¼ 0:28; Po0:05), SE¼ 26.8.
Note: BNP log scale used due to wide variation in values.
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Ascertainment of the cut-off value for N-T
proBNP that predicts mPAP of 25mmHg on
cardiac catheter (i.e., mPAP diagnostic of
PAH by NIH criteria)
Fig. 5 shows the ROC curve for N-T proBNP in SSc
patients with PAH compared to controls. A cut-off
value of 395.34 pg/ml gave a test sensitivity of 0.69
and specificity of 1.0. The high specificity of this
test implied that all patients with level of less than
395 pg/ml did not have PAH. The area under the
ROC curve by Wilcoxon’s estimate (95% confidence
interval) was 0.91. This suggested a good negative
predictive value for the assay.
Discussion
Our pilot study demonstrated a positive correlation
between haemodynamic parameters of RV dysfunc-
tion and plasma N-T proBNP levels in 23 SSc
patients with PAH. There was a significant correla-
tion between N-T proBNP levels and the severity of
PAH as judged by elevations in mPAP, PVR and
RVEDP on cardiac catheter. In addition, we found
that SScPAH patients with severe functional im-
pairment, with a SMWT o250m (corresponding to
modified NYHA grade III/IV dyspnoea) had a 10-fold
increase in levels compared to patients with SMWT
4250m (corresponding to NYHA dyspnoea grades
II/III). Our findings concur with those of Nagaya
et al,6,7 who correlated plasma BNP levels with
mPAPs and functional capacity in PPH patients.
These authors used an ELISA assay for plasma BNP,
not the N-terminal propeptide ligand, and sug-
gested that raised levels are associated with a poor
prognosis in PPH. Interestingly, the same authors19
showed a correlation with the severity of PAH in 34
patients with chronic thromboembolic disease,
with levels falling when the RV impairment was
rectified after thromboendarterectomy.
As haemodynamic indices of RV dysfunction in
SScPAH are known to predict survival,20 plasma N-T
proBNP levels in SScPAH may have a similar
prognostic role. This is supported by the finding
that our patients with high N-T proBNP levels had
severe limitation of their functional capacity as
measured by the SMWT. Longitudinal observations
from our actively followed up cohort of SScPAH
patients indicate that some SSc patients with
markedly elevated mean pulmonary artery pres-
sures clinically do well, and some with less
elevated pressures succumb. The scatter distribu-
tion of plasma N-T proBNP levels raises the exciting
possibility that those with greater RV dysfunction
but similar mPAPs may have higher levels of N-T
proBNP. This was intimated in our group of four
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Figure 3 Correlation between N-T proBNP values (pg/
ml) and RVEDP in mmHg. Correlation coefficient r ¼ 0:59
(r2 ¼ 0:35; Po0:05), SE¼ 68. Note: BNP log scale used due
to wide variation in values.
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Figure 4 Comparison of plasma N-T proBNP levels (pg/
ml) in 23 SSc patients with catheter-diagnosed PAH with
(a) SMWTo250m (n ¼ 14) and (b) SMWT4250m (n ¼ 9).
Mean BNP value in pg/ml given above bars for each
group.
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Figure 5 ROC curve for N-T proBNP in SSc patients in the
diagnosis of pulmonary hypertension. True-positive rates
and false-positive rates are plotted to obtain a cut-off
value of 395.34 pg/ml.
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patients with mPAP 460mmHg who had a wide
variation in their N-T proBNP levels. On closer study
of the clinical characteristics of this subgroup, the
two patients with high levels had a SMWT of
o200m (NYHA grade IV symptoms). None of these
patients had concomitant left ventricular dysfunc-
tion or pulmonary fibrosis on HRCT. In the future, it
may be possible to risk stratify individuals with
SScPAH, with patients with elevated plasma N-T
proBNP levels comprising a readily identifiable poor
prognostic group. Currently, SMWTs and repeated
invasive haemodynamic studies are used to serially
assess therapeutic response and disease progres-
sion. The former procedure is cumbersome and the
latter functional test prone to day-to-day fluctua-
tions. If plasma N-T proBNP levels have an even
equivalent prognostic accuracy, then our ability to
monitor patients and adjust therapy with SScPAH
will be significantly improved.
Along with transforming growth factor b and
endothelin-1, BNP has been implicated in the
pathogenesis of cardiac fibrosis.21,22 We found
elevated levels of this peptide in the background
SSc population, and markedly elevated levels in the
presence of PAH. The mean level in the SSc control
patients was 347 pg/ml and 3365 pg/ml in patients
with PAH. The values for the upper range of normal
suggested by the manufacturers of the NT-proBNP
Elecsys assay, which will be recommended as a cut-
off to screen for patients with heart failure in
Europe and USA in the near future (Dr. B Agrawal,
Roche, UK, personal communication) are 93 pg/ml
for males and 144 pg/ml for females. The finding
that N-T proBNP levels were 2.5 times the normal
upper limit in the non-PAH SSc patients strengthens
the suggestion that BNP acts directly on the
myocardium to inhibit myocyte hypertrophy and
fibrosis. The finding that the levels are elevated in
the control SSc patients implies that either the
normal ranges for N-T proBNP do not apply in this
population, or that there may be a subclinical
activation of N-T proBNP production occurring in
SSc patients without the stimulus of pressure
loading of the right ventricle. The former scenario
is interesting given that natriuretic peptide recep-
tors (NPRs) have been found to have an important
role in collagen synthesis and inhibition within
cardiac fibroblasts and myocytes.23,24 There are
three classes of NPRs, with BNP activity mediated
predominantly through NPR A and C.25 NPR-A
knockout mice demonstrate cardiac hypertrophy
and LV dilatation, and this response has been found
to be reduced by chronic treatment with enalapril,
frusemide and losartan.26 It has also been shown
that within the context of RV hypertrophy, NPRs are
downregulated within the endocardium as a mod-
ulatory measure.27 Enhancement of natriuretic
peptide activity may be achieved through the
inhibition of metabolism by neutral endopeptidase.
Hence, endopeptidase inhibitors such as
omapatrilat or candoxatril28 may be beneficial by
arresting cardiac hypertrophy. Similarly, the re-
combinant B-type natriuretic peptides such as
Nesiritide29 may have therapeutic potential in
slowing progression of RV dysfunction amongst SSc
patients by inhibition of cardiac fibroblast prolif-
eration and collagen deposition, which is known to
occur in this disease.
Limitations
This was a small pilot study, where only limited
conclusions can be drawn due to the lack of
statistical power. Not all control subjects with SSc
underwent cardiac catheterisation and hence PAH
may have been missed in these non-catheterised
patients. However, echocardiography, DLCO and
clinical assessment including CXRs and ECG were all
normal in these individuals, diminishing the possi-
bility that they had subclinical PAH. Due to the
limitation of the design, it is not known whether a
single elevated N-T proBNP value is predictive of
survival in patients with right ventricular dysfunc-
tion in the future. In order to investigate this
further, one would be required to follow-up SScPAH
patients with varying N-T proBNP levels but similar
mPAPs on catheterisation serially over a period of
time.
Conclusions
Plasma N-terminal pro-brain natriuretic peptide
levels significantly correlated with haemodynamic
measures of disease severity in systemic sclerosis-
related pulmonary hypertension (SScPAH). Although
the levels of this peptide were elevated twice the
upper range of normal in the background SSc
population, this test has a good negative predictive
value, suggesting that patients with a brain
natriuretic peptide (BNP) value below a certain
cut-off value are highly unlikely to have pulmonary
arterial hypertension. The assay used in this study
had good internal validity and was feasible for use
in busy clinical settings. Measurement of this
peptide may provide important prognostic informa-
tion and help guide therapy in SScPAH patients. Our
results justify a larger future study to confirm the
above findings and further investigate the prog-
nostic role of BNP in SScPAH.
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